A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Running, not enrolling · Phase 3

Conditions studied: Prurigo Nodularis

In brief

The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).

Key facts

Study ID

NCT04204616

Run by

Galderma R&D

People needed

500

Starts

2021-01-11

Expected to finish

2026-10-26

Last updated by the study team

2025-11-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who may benefit from study participation in the opinion of the investigator and participated in a prior nemolizumab study for PN including: (a). Participants who completed the treatment period in a phase 3 pivotal study (NCT04501666 or NCT04501679) and enroll within 56 days OR (b). Participants who were previously randomized in the nemolizumab phase 2a PN study (NCT03181503) OR (c). Participants who completed through Week 24 of the phase 3b durability study (NCT05052983) or who exit the study due to relapse may be eligible to re-enter in the LTE study within 28 days of exiting the durability study (selected countries/ selected sites)
• Female participants of childbearing potential (that is, fertile, following menarche and until becoming post-menopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection
• Participant willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol, including periodic weekly recordings by the participant using an electronic handheld device provided for this study
• Understand and sign an informed consent form (ICF) before any investigational procedure(s) are performed

You may not qualify if…

• Participants who, during their participation in a prior nemolizumab study, experienced an adverse event (AE) which in the opinion of the investigator could indicate that continued treatment with nemolizumab may present an unreasonable risk for the participant
• Body weight < 30 kg
• Pregnant women (positive pregnancy test result at screening or baseline visit or re-entry Week R0 visit), breastfeeding women, or women planning a pregnancy during the clinical study
• Any medical or psychological condition that may put the participant at significant risk according to the investigator's judgment, if he/she participates in the clinical study, or may interfere with study assessments (example, poor venous access or needle-phobia)
• Planning or expected to have a major surgical procedure during the clinical study
• Participants unwilling to refrain from using prohibited medications during the clinical study
• History of alcohol or substance abuse within 6 months prior to the screening visit or re-entry Week R0 visit

Where it is running

• Galderma Investigational Site — Birmingham, Alabama, United States
• Galderma Investigational Site — Fountain Valley, California, United States
• Galderma Investigational Site — Los Angeles, California, United States
• Galderma Investigational Site — San Diego, California, United States
• Galderma Investigational Site — San Diego, California, United States
• Galderma Investigational Site — Santa Monica, California, United States
• Galderma Investigational Site — Washington D.C., District of Columbia, United States
• Galderma Investigational Site — Aventura, Florida, United States
• Galderma Investigational Site — Delray Beach, Florida, United States
• Galderma Investigational Site — Hollywood, Florida, United States
• Galderma Investigational Site — Largo, Florida, United States
• Galderma Investigational Site — Miami, Florida, United States
• Galderma Investigational Site — Miami, Florida, United States
• Galderma Investigational Site — North Miami Beach, Florida, United States
• Galderma Investigational Site — Ormond Beach, Florida, United States
• Galderma Investigational Site — Pembroke Pines, Florida, United States
• Galderma Investigational Site — Tampa, Florida, United States
• Galderma Investigational Galderma Investigational Site — Columbus, Georgia, United States
• Galderma Investigational Site — Macon, Georgia, United States
• Galderma Investigational Site — Newnan, Georgia, United States
• Galderma Investigational Site — Chicago, Illinois, United States
• Galderma Investigational Galderma Investigational Site — Chicago, Illinois, United States
• Galderma I Galderma Investigational Site — Lake Bluff, Illinois, United States
• Galderma Investigational Site — Indianapolis, Indiana, United States
• Galderma Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.